Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
NASA's Perseverance Mars rover could break the record for miles driven on another planet - 2Federal judge upholds Hawaii's new climate change tax on cruise passengers
- 3Last Christmas, 3 million viewers watched a Chiefs love story — will Bills fans fall just as hard this year?
- 4Instructions to Augment the Presentation of Your Kona SUV
- 5Scientists solve the mystery of 'impossible' merger of 'forbidden' black holes
- This professional Santa's dream of spreading holiday cheer fuels stroke recovery
- Paris Agreement target off the table, report says
- Pick Your Favored kind of soup
- Dad issues urgent plea to find stem cell donor for his son
- Al-Sharaa denies he called for 80% of Syrians to return from Germany
- Does physics say that free will doesn't exist?
- New UPS distribution center in Taiwan doubles capacity, productivity
- A mom stopped giving her kids snacks — and sparked a debate about eating habits
- Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
